VYNE Therapeutics (NASDAQ:VYNE) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a $5.75 target price on the stock.

Separately, BTIG Research started coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $8.00 target price for the company.

VYNE Therapeutics Stock Down 2.5 %

NASDAQ VYNE opened at $2.33 on Thursday. The stock’s 50 day moving average is $2.78 and its 200 day moving average is $2.50. The firm has a market capitalization of $34.37 million, a PE ratio of -2.71 and a beta of 1.13. VYNE Therapeutics has a twelve month low of $1.57 and a twelve month high of $4.30.

VYNE Therapeutics (NASDAQ:VYNE) last released its earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.14 million. On average, research analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current year.

Insider Activity

In other news, Director Patrick G. Lepore purchased 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average price of $2.92 per share, for a total transaction of $43,800.00. Following the purchase, the director now directly owns 51,472 shares in the company, valued at approximately $150,298.24. This trade represents a 41.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC grew its holdings in shares of VYNE Therapeutics by 4.8% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares during the last quarter. Jane Street Group LLC purchased a new stake in VYNE Therapeutics during the 4th quarter valued at $68,000. XTX Topco Ltd bought a new stake in shares of VYNE Therapeutics in the 4th quarter worth $70,000. Bridgeway Capital Management LLC purchased a new position in shares of VYNE Therapeutics in the fourth quarter worth $124,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of VYNE Therapeutics during the fourth quarter valued at $516,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.